(Below N is a link to NCBI taxonomic web page and E link to ESTHER at designed phylum.) > cellular organisms: NE > Bacteria: NE > Terrabacteria group: NE > Firmicutes: NE > Bacilli: NE > Bacillales: NE > Staphylococcaceae: NE > Staphylococcus: NE > Staphylococcus aureus: NE
Warning: This entry is a compilation of different species or line or strain with more than 90% amino acid identity. You can retrieve all strain data
(Below N is a link to NCBI taxonomic web page and E link to ESTHER at designed phylum.) Staphylococcus aureus subsp. aureus N315: N, E.
Staphylococcus aureus subsp. aureus TCH60: N, E.
Staphylococcus aureus subsp. aureus JKD6159: N, E.
Staphylococcus aureus subsp. aureus NCTC 8325: N, E.
Staphylococcus aureus subsp. aureus str. Newman: N, E.
Staphylococcus aureus 04-02981: N, E.
Staphylococcus aureus subsp. aureus USA300_TCH959: N, E.
Staphylococcus aureus subsp. aureus USA300: N, E.
Staphylococcus aureus subsp. aureus USA300_TCH1516: N, E.
Staphylococcus aureus subsp. aureus JH1: N, E.
Staphylococcus aureus subsp. aureus ED133: N, E.
Staphylococcus aureus subsp. aureus ST398: N, E.
Staphylococcus aureus subsp. aureus DR10: N, E.
Staphylococcus aureus subsp. aureus 71193: N, E.
Staphylococcus aureus RF122: N, E.
Staphylococcus aureus subsp. aureus ED98: N, E.
Staphylococcus aureus subsp. aureus Mu3: N, E.
Staphylococcus aureus subsp. aureus JH9: N, E.
Staphylococcus aureus subsp. aureus 68-397: N, E.
Staphylococcus aureus subsp. aureus M1015: N, E.
Staphylococcus aureus subsp. aureus A017934/97: N, E.
Staphylococcus aureus subsp. aureus M876: N, E.
Staphylococcus aureus A9763: N, E.
Staphylococcus aureus A5948: N, E.
Staphylococcus aureus A9754: N, E.
Staphylococcus aureus subsp. aureus C160: N, E.
Staphylococcus aureus subsp. aureus C427: N, E.
Staphylococcus aureus subsp. aureus 55/2053: N, E.
Staphylococcus aureus A8115: N, E.
Staphylococcus aureus A9765: N, E.
Staphylococcus aureus subsp. aureus D139: N, E.
Staphylococcus aureus A9781: N, E.
Staphylococcus aureus subsp. aureus TCH130: N, E.
Staphylococcus aureus subsp. aureus WW2703/97: N, E.
Staphylococcus aureus subsp. aureus M899: N, E.
Staphylococcus aureus A8819: N, E.
Staphylococcus aureus A8117: N, E.
Staphylococcus aureus A9719: N, E.
Staphylococcus aureus A6300: N, E.
Staphylococcus aureus subsp. aureus 65-1322: N, E.
Staphylococcus aureus C0673: N, E.
Staphylococcus aureus subsp. aureus MW2: N, E.
Staphylococcus aureus subsp. aureus MSSA476: N, E.
Staphylococcus aureus subsp. aureus ATCC 51811: N, E.
Staphylococcus aureus subsp. aureus H19: N, E.
Staphylococcus aureus A9635: N, E.
Staphylococcus aureus subsp. aureus MN8: N, E.
Staphylococcus aureus subsp. aureus EMRSA16: N, E.
Staphylococcus aureus subsp. aureus MRSA252: N, E.
Staphylococcus aureus subsp. aureus 58-424: N, E.
Staphylococcus aureus subsp. aureus Btn1260: N, E.
Staphylococcus aureus subsp. aureus C101: N, E.
Staphylococcus aureus subsp. aureus M809: N, E.
Staphylococcus aureus subsp. aureus WBG10049: N, E.
Staphylococcus aureus subsp. aureus E1410: N, E.
Staphylococcus aureus D30: N, E.
Staphylococcus aureus subsp. aureus str. JKD6008: N, E.
Staphylococcus aureus subsp. aureus ATCC BAA-39: N, E.
Staphylococcus aureus subsp. aureus COL: N, E.
Staphylococcus aureus subsp. aureus TW20: N, E.
Staphylococcus aureus subsp. aureus Mu50: N, E.
Staphylococcus aureus A6224: N, E.
Staphylococcus aureus A10102: N, E.
Staphylococcus aureus A8796: N, E.
Staphylococcus aureus A5937: N, E.
Staphylococcus aureus A9299: N, E.
Staphylococcus aureus 930918-3: N, E.
Staphylococcus aureus subsp. aureus MRSA177: N, E.
Staphylococcus aureus subsp. aureus MRSA131: N, E.
Staphylococcus aureus subsp. aureus TCH70: N, E.
Staphylococcus aureus subsp. aureus ECT-R 2: N, E.
Staphylococcus aureus subsp. aureus CGS00: N, E.
Staphylococcus aureus subsp. aureus CGS01: N, E.
Staphylococcus aureus subsp. aureus CGS03: N, E.
Staphylococcus aureus M0562: N, E.
Staphylococcus aureus M1: N, E.
Staphylococcus aureus M0329: N, E.
Staphylococcus aureus subsp. aureus CIG1114: N, E.
Staphylococcus aureus subsp. aureus SA957: N, E.
Staphylococcus aureus M1394: N, E.
Staphylococcus aureus M1450: N, E.
Staphylococcus aureus M0066: N, E.
Staphylococcus aureus M0633: N, E.
Staphylococcus aureus subsp. aureus 21264: N, E.
Staphylococcus aureus M0216: N, E.
Staphylococcus aureus subsp. aureus VRS1: N, E.
Staphylococcus aureus M0998: N, E.
Staphylococcus aureus M0547: N, E.
Staphylococcus aureus M0450: N, E.
Staphylococcus aureus M1044: N, E.
Staphylococcus aureus subsp. aureus CIGC348: N, E.
Staphylococcus aureus HI010: N, E.
Staphylococcus aureus M1533: N, E.
Staphylococcus aureus subsp. aureus VCU006: N, E.
Staphylococcus aureus M0934: N, E.
Staphylococcus aureus subsp. aureus 21345: N, E.
Staphylococcus aureus M0213: N, E.
Staphylococcus aureus M0468: N, E.
Staphylococcus aureus HI111: N, E.
Staphylococcus aureus M0438: N, E.
Staphylococcus aureus M0769: N, E.
Staphylococcus aureus subsp. aureus 21232: N, E.
Staphylococcus aureus M0571: N, E.
Staphylococcus aureus subsp. aureus IS-125: N, E.
Staphylococcus aureus M0077: N, E.
Staphylococcus aureus subsp. aureus CIG1770: N, E.
Staphylococcus aureus subsp. aureus CIG1524: N, E.
Staphylococcus aureus M0770: N, E.
Staphylococcus aureus M1244: N, E.
Staphylococcus aureus M0173: N, E.
Staphylococcus aureus M1463: N, E.
Staphylococcus aureus M0330: N, E.
Staphylococcus aureus M0964: N, E.
Staphylococcus aureus M0478: N, E.
Staphylococcus aureus KT/Y21: N, E.
Staphylococcus aureus M1373: N, E.
Staphylococcus aureus subsp. aureus IS-99: N, E.
Staphylococcus aureus M0035: N, E.
Staphylococcus aureus HI049B: N, E.
Staphylococcus aureus SA16: N, E.
Staphylococcus aureus M0363: N, E.
Staphylococcus aureus KT/314250: N, E.
Staphylococcus aureus M0460: N, E.
Staphylococcus aureus subsp. aureus VRS11a: N, E.
Staphylococcus aureus M0877: N, E.
Staphylococcus aureus M0822: N, E.
Staphylococcus aureus subsp. aureus 21196: N, E.
Staphylococcus aureus subsp. aureus CIG1233: N, E.
Staphylococcus aureus M1007: N, E.
Staphylococcus aureus M1170: N, E.
Staphylococcus aureus M1092: N, E.
Staphylococcus aureus M0237: N, E.
Staphylococcus aureus subsp. aureus LGA251: N, E.
Staphylococcus aureus SA_ST125_MupR: N, E.
Staphylococcus aureus M0351: N, E.
Staphylococcus aureus M1228: N, E.
Staphylococcus aureus M0060: N, E.
Staphylococcus aureus subsp. aureus 112808A: N, E.
Staphylococcus aureus subsp. aureus IS-91: N, E.
Staphylococcus aureus M0529: N, E.
Staphylococcus aureus subsp. aureus 21172: N, E.
Staphylococcus aureus M1010: N, E.
Staphylococcus aureus subsp. aureus CO-08: N, E.
Staphylococcus aureus M1076: N, E.
Staphylococcus aureus subsp. aureus CIGC340D: N, E.
Staphylococcus aureus M0489: N, E.
Staphylococcus aureus subsp. aureus CIG1150: N, E.
Staphylococcus aureus subsp. aureus IS-111: N, E.
Staphylococcus aureus M1078: N, E.
Staphylococcus aureus subsp. aureus CIG547: N, E.
Staphylococcus aureus subsp. aureus 21193: N, E.
Staphylococcus aureus M0312: N, E.
Staphylococcus aureus subsp. aureus CIG1835: N, E.
Staphylococcus aureus subsp. aureus 21269: N, E.
Staphylococcus aureus M0364: N, E.
Staphylococcus aureus subsp. aureus DSM 20231: N, E.
Staphylococcus aureus subsp. aureus CIG1612: N, E.
Staphylococcus aureus subsp. aureus CO-23: N, E.
Staphylococcus aureus M1142: N, E.
Staphylococcus aureus M0055: N, E.
Staphylococcus aureus M1466: N, E.
Staphylococcus aureus M0029: N, E.
Staphylococcus aureus M0493: N, E.
Staphylococcus aureus subsp. aureus 122051: N, E.
Staphylococcus aureus M1321: N, E.
Staphylococcus aureus M0347: N, E.
Staphylococcus aureus M0676: N, E.
Staphylococcus aureus M0719: N, E.
Staphylococcus aureus M1578: N, E.
Staphylococcus aureus M0580: N, E.
Staphylococcus aureus M1255: N, E.
Staphylococcus aureus M0375: N, E.
Staphylococcus aureus M0280: N, E.
Staphylococcus aureus M0326: N, E.
Staphylococcus aureus S100: N, E.
Staphylococcus aureus M0628: N, E.
Staphylococcus aureus M0871: N, E.
Staphylococcus aureus M1481: N, E.
Staphylococcus aureus subsp. aureus 21252: N, E.
Staphylococcus aureus M0171: N, E.
Staphylococcus aureus M1556: N, E.
Staphylococcus aureus M0494: N, E.
Staphylococcus aureus M1193: N, E.
Staphylococcus aureus M0001: N, E.
Staphylococcus aureus subsp. aureus CIG1214: N, E.
Staphylococcus aureus M0823: N, E.
Staphylococcus aureus subsp. aureus CIGC93: N, E.
Staphylococcus aureus subsp. aureus CIG1213: N, E.
Staphylococcus aureus M1248: N, E.
Staphylococcus aureus subsp. aureus CIG1605: N, E.
Staphylococcus aureus M0240: N, E.
Staphylococcus aureus M1037: N, E.
Staphylococcus aureus subsp. aureus 21189: N, E.
Staphylococcus aureus M0294: N, E.
Staphylococcus aureus Bmb9393: N, E.
Staphylococcus aureus B40950: N, E.
Staphylococcus aureus 08BA02176: N, E.
Staphylococcus aureus subsp. aureus 21272: N, E.
Staphylococcus aureus M0252: N, E.
Staphylococcus aureus M1188: N, E.
Staphylococcus aureus M0328: N, E.
Staphylococcus aureus M0350: N, E.
Staphylococcus aureus M1563: N, E.
Staphylococcus aureus M1253: N, E.
Staphylococcus aureus subsp. aureus CM05: N, E.
Staphylococcus aureus M0531: N, E.
Staphylococcus aureus subsp. aureus CBD-635: N, E.
Staphylococcus aureus subsp. aureus IS-157: N, E.
Staphylococcus aureus M1083: N, E.
Staphylococcus aureus subsp. aureus str. Newbould 305: N, E.
Staphylococcus aureus M0687: N, E.
Staphylococcus aureus subsp. aureus 21283: N, E.
Staphylococcus aureus M0944: N, E.
Staphylococcus aureus subsp. aureus VRS3a: N, E.
Staphylococcus aureus HI013: N, E.
Staphylococcus aureus CN79: N, E.
Staphylococcus aureus subsp. aureus 21262: N, E.
Staphylococcus aureus M1199: N, E.
Staphylococcus aureus subsp. aureus PSP1996: N, E.
Staphylococcus aureus M1275: N, E.
Staphylococcus aureus subsp. aureus Z172: N, E.
Staphylococcus aureus subsp. aureus CIG1267: N, E.
Staphylococcus aureus subsp. aureus IS-189: N, E.
Staphylococcus aureus subsp. aureus SA40: N, E.
Staphylococcus aureus M0103: N, E.
Staphylococcus aureus M0334: N, E.
Staphylococcus aureus M1068: N, E.
Staphylococcus aureus M1167: N, E.
Staphylococcus aureus M0200: N, E.
Staphylococcus aureus M0404: N, E.
Staphylococcus aureus M1521: N, E.
Staphylococcus aureus subsp. aureus IS-M: N, E.
Staphylococcus aureus subsp. aureus IS-3: N, E.
Staphylococcus aureus CA-347: N, E.
Staphylococcus aureus M0045: N, E.
Staphylococcus aureus M0197: N, E.
Staphylococcus aureus M0396: N, E.
Staphylococcus aureus M0279: N, E.
Staphylococcus aureus subsp. aureus VC40: N, E.
Staphylococcus aureus M0622: N, E.
Staphylococcus aureus KLT6: N, E.
Staphylococcus aureus M0235: N, E.
Staphylococcus aureus subsp. aureus 11819-97: N, E.
Staphylococcus aureus M0374: N, E.
Staphylococcus aureus M0424: N, E.
Staphylococcus aureus subsp. aureus 21201: N, E.
Staphylococcus aureus subsp. aureus 21282: N, E.
Staphylococcus aureus M1062: N, E.
Staphylococcus aureus M1109: N, E.
Staphylococcus aureus HI022: N, E.
Staphylococcus aureus M0900: N, E.
Staphylococcus aureus M0831: N, E.
Staphylococcus aureus subsp. aureus T0131: N, E.
Staphylococcus aureus subsp. aureus VRS8: N, E.
Staphylococcus aureus M1103: N, E.
Staphylococcus aureus M0510: N, E.
Staphylococcus aureus M0648: N, E.
Staphylococcus aureus M0646: N, E.
Staphylococcus aureus S123: N, E.
Staphylococcus aureus subsp. aureus VRS7: N, E.
Staphylococcus aureus M1451: N, E.
Staphylococcus aureus B147830: N, E.
Staphylococcus aureus M0892: N, E.
Staphylococcus aureus M0660: N, E.
Staphylococcus aureus M1095: N, E.
Staphylococcus aureus subsp. aureus CIG1176: N, E.
Staphylococcus aureus subsp. aureus VRS2: N, E.
Staphylococcus aureus subsp. aureus 6850: N, E.
Staphylococcus aureus M0391: N, E.
Staphylococcus aureus subsp. aureus CIG290: N, E.
Staphylococcus aureus M0539: N, E.
Staphylococcus aureus M0978: N, E.
Staphylococcus aureus M1531: N, E.
Staphylococcus aureus subsp. aureus 21318: N, E.
Staphylococcus aureus M0799: N, E.
Staphylococcus aureus M1016: N, E.
Staphylococcus aureus subsp. aureus IS-160: N, E.
Staphylococcus aureus M1286: N, E.
Staphylococcus aureus M1544: N, E.
Staphylococcus aureus subsp. aureus 21310: N, E.
Staphylococcus aureus subsp. aureus ST228: N, E.
Staphylococcus aureus M1367: N, E.
Staphylococcus aureus subsp. aureus VRS9: N, E.
Staphylococcus aureus subsp. aureus 21202: N, E.
Staphylococcus aureus M0075: N, E.
Staphylococcus aureus M1359: N, E.
Staphylococcus aureus M1063: N, E.
Staphylococcus aureus M1229: N, E.
Staphylococcus aureus M0340: N, E.
Staphylococcus aureus M0427: N, E.
Staphylococcus aureus M0586: N, E.
Staphylococcus aureus subsp. aureus CIG2018: N, E.
Staphylococcus aureus M1462: N, E.
Staphylococcus aureus M0250: N, E.
Staphylococcus aureus subsp. aureus IS-88: N, E.
Staphylococcus aureus M0536: N, E.
Staphylococcus aureus M0528: N, E.
Staphylococcus aureus HI049: N, E.
Staphylococcus aureus M1223: N, E.
Staphylococcus aureus subsp. aureus 21305: N, E.
Staphylococcus aureus M0104: N, E.
Staphylococcus aureus M1291: N, E.
Staphylococcus aureus HI010B: N, E.
Staphylococcus aureus S130: N, E.
Staphylococcus aureus M1093: N, E.
Staphylococcus aureus M0177: N, E.
Staphylococcus aureus subsp. aureus 21331: N, E.
Staphylococcus aureus M1015: N, E.
Staphylococcus aureus M0927: N, E.
Staphylococcus aureus subsp. aureus 21343: N, E.
Staphylococcus aureus subsp. aureus 21340: N, E.
Staphylococcus aureus M0844: N, E.
Staphylococcus aureus subsp. aureus IS-24: N, E.
Staphylococcus aureus M1520: N, E.
Staphylococcus aureus subsp. aureus 21259: N, E.
Staphylococcus aureus M1061: N, E.
Staphylococcus aureus subsp. aureus CIGC341D: N, E.
Staphylococcus aureus S1: N, E.
Staphylococcus aureus B40723: N, E.
Staphylococcus aureus M1320: N, E.
Staphylococcus aureus M1119: N, E.
Staphylococcus aureus M0367: N, E.
Staphylococcus aureus M0408: N, E.
Staphylococcus aureus M0239: N, E.
Staphylococcus aureus subsp. aureus CIG1750: N, E.
Staphylococcus aureus M1322: N, E.
Staphylococcus aureus subsp. aureus 21333: N, E.
Staphylococcus aureus M0602: N, E.
Staphylococcus aureus M1407: N, E.
Staphylococcus aureus subsp. aureus CIGC128: N, E.
Staphylococcus aureus M0108: N, E.
Staphylococcus aureus subsp. aureus 103564: N, E.
Staphylococcus aureus subsp. aureus VRS5: N, E.
Staphylococcus aureus M0212: N, E.
Staphylococcus aureus S94: N, E.
Staphylococcus aureus M0663: N, E.
Staphylococcus aureus subsp. aureus VRS10: N, E.
Staphylococcus aureus M1224: N, E.
Staphylococcus aureus subsp. aureus 21235: N, E.
Staphylococcus aureus M0415: N, E.
Staphylococcus aureus B53639: N, E.
Staphylococcus aureus subsp. aureus CIG1096: N, E.
Staphylococcus aureus subsp. aureus VRS11b: N, E.
Staphylococcus aureus subsp. aureus 21236: N, E.
Staphylococcus aureus M0943: N, E.
Staphylococcus aureus M0150: N, E.
Staphylococcus aureus subsp. aureus 21178: N, E.
Staphylococcus aureus M0154: N, E.
Staphylococcus aureus M0565: N, E.
Staphylococcus aureus subsp. aureus IS-105: N, E.
Staphylococcus aureus M1311: N, E.
Staphylococcus aureus subsp. aureus 21342: N, E.
Staphylococcus aureus M1374: N, E.
Staphylococcus aureus subsp. aureus IS-122: N, E.
Staphylococcus aureus M0306: N, E.
Staphylococcus aureus M0192: N, E.
Staphylococcus aureus M1405: N, E.
Staphylococcus aureus M1565: N, E.
Staphylococcus aureus O46: N, E.
Staphylococcus aureus M0946: N, E.
Staphylococcus aureus subsp. aureus CIGC345D: N, E.
Staphylococcus aureus M0210: N, E.
Staphylococcus aureus M1198: N, E.
Staphylococcus aureus subsp. aureus VRS4: N, E.
Staphylococcus aureus M0221: N, E.
Staphylococcus aureus M1256: N, E.
Staphylococcus aureus subsp. aureus 21209: N, E.
Staphylococcus aureus HI049C: N, E.
Staphylococcus aureus subsp. aureus MRGR3: N, E.
Staphylococcus aureus HIF003_B2N-C: N, E.
Staphylococcus aureus M0584: N, E.
Staphylococcus aureus subsp. aureus VRS6: N, E.
Staphylococcus aureus subsp. aureus 21334: N, E.
Staphylococcus aureus M0780: N, E.
Staphylococcus aureus M1034: N, E.
Staphylococcus aureus M0288: N, E.
Staphylococcus aureus M1036: N, E.
Staphylococcus aureus subsp. aureus CIG1769: N, E.
Staphylococcus aureus M0270: N, E.
Staphylococcus aureus M1277: N, E.
Staphylococcus aureus subsp. aureus CIG149: N, E.
Staphylococcus aureus subsp. aureus IS-55: N, E.
Staphylococcus aureus M1510: N, E.
Staphylococcus aureus subsp. aureus CN1: N, E.
Staphylococcus aureus M1215: N, E.
Staphylococcus aureus M1060: N, E.
Staphylococcus aureus M1216: N, E.
Staphylococcus aureus M0102: N, E.
Staphylococcus aureus M0273: N, E.
Staphylococcus aureus M0695: N, E.
Staphylococcus aureus M0006: N, E.
Staphylococcus aureus M0953: N, E.
Staphylococcus aureus M0513: N, E.
Staphylococcus aureus M0455: N, E.
Staphylococcus aureus subsp. aureus 091751: N, E.
Staphylococcus aureus M0692: N, E.
Staphylococcus aureus M0792: N, E.
Staphylococcus aureus subsp. aureus HO 5096 0412: N, E.
Staphylococcus aureus subsp. aureus CIG1165: N, E.
Staphylococcus aureus M0999: N, E.
Staphylococcus aureus subsp. aureus 21194: N, E.
Staphylococcus aureus subsp. aureus 21200: N, E.
Staphylococcus aureus M1309: N, E.
Staphylococcus aureus M0673: N, E.
Staphylococcus aureus M1126: N, E.
Staphylococcus aureus M1257: N, E.
Staphylococcus aureus HI168: N, E.
Staphylococcus aureus subsp. aureus M013: N, E.
Staphylococcus aureus subsp. aureus 21195: N, E.
Staphylococcus aureus M0467: N, E.
Staphylococcus aureus subsp. aureus CIG1500: N, E.
Staphylococcus aureus subsp. aureus 21266: N, E.
Staphylococcus aureus M0994: N, E.
Staphylococcus aureus O11: N, E.
Staphylococcus aureus M0144: N, E.
Staphylococcus aureus M1064: N, E.
Staphylococcus aureus subsp. aureus CIG1242: N, E.
Staphylococcus aureus subsp. aureus CIG1057: N, E.
Staphylococcus aureus subsp. aureus CO-98: N, E.
Staphylococcus aureus M1057: N, E.
Staphylococcus aureus subsp. aureus: N, E.
Staphylococcus aureus subsp. aureus ST772-MRSA-V: N, E.
Staphylococcus aureus subsp. anaerobius: N, E.
Staphylococcus simulans: N, E.
Staphylococcus simulans UMC-CNS-990: N, E.
Staphylococcus simulans ACS-120-V-Sch1: N, E.
Molecular evidence
Database
No mutation 4 structures(e.g. : 6KSI, 6KSL, 6KSM... more)(less) 6KSI: crystal structure of pathogenic Staphylococcus aureus lipase. Native, 6KSL: crystal structure of pathogenic Staphylococcus aureus lipase. Inactive S116A mutant, 6KSM: crystal structure of pathogenic Staphylococcus aureus lipase. SAL orlistat complex, 8K7Q: Staphylococcus aureus lipase S116A inactive mutant-PSA complex No kinetic
LegendThis sequence has been compared to family alignement (MSA) red => minority aminoacid blue => majority aminoacid color intensity => conservation rate title => sequence position(MSA position)aminoacid rate Catalytic site Catalytic site in the MSA GQNSPEKPTDKNTDNKQLIKDALQAPKTRSTTNAAADAKKVRPLKANQVQ PLNKYPVVFVHGFLGLVGDNAPALYPNYWGGNKFKVIEELRKQGYNVHQA SVSAFGSNYDRAVELYYYIKGGRVDYGAAHAAKYGHERYGKTYKGIMPNW EPGKKVHLVGHSMGGQTIRLMEEFLRNGNKEEIAYHKAHGGEISPLFTGG HNNMVASITTLATPHNGSQAADKFGNTEAVRKIMFALNRFMGNKYSNIDL GLTQWGFKQLPNESYIDYIKRVSKSKIWTSDDNAAYDLTLDGSAKLNNMT SMNPNITYTTYTGVSSHTGPLGYENPDLGTFFLMATTSRIIGHDAREEWR KNDGVVPVISSLHPSNQPFVNVTNDEPATRRGIWQVKPIIQGWDHVDFIG VDFLDFKRKGAELANFYTGIINDLLRVEATESKGTQLKAS
References
23 moreTitle: The Phospholipase A1 Activity of Glycerol Ester Hydrolase (Geh) Is Responsible for Extracellular 2-12(S)-Methyltetradecanoyl-Lysophosphatidylglycerol Production in Staphylococcus aureus Subramanian C, Frank MW, Yun MK, Rock CO Ref: mSphere, :e0003123, 2023 : PubMed
Phosphatidylglycerol (PG) is the major membrane phospholipid of Staphylococcus aureus and predominately consists of molecular species with <=16-carbon acyl chains in the 1-position and anteiso 12(S)-methyltetradecaonate (a15) esterified at the 2-position. The analysis of the growth media for PG-derived products shows S. aureus releases essentially pure 2-12(S)-methyltetradecanoyl-sn-glycero-3-phospho-1'-sn-glycerol (a15:0-LPG) derived from the hydrolysis of the 1-position of PG into the environment. The cellular lysophosphatidylglycerol (LPG) pool is dominated by a15-LPG but also consists of <=16-LPG species arising from the removal of the 2-position. Mass tracing experiments confirmed a15-LPG was derived from isoleucine metabolism. A screen of candidate secreted lipase knockout strains pinpointed glycerol ester hydrolase (geh) as the gene required for generating extracellular a15-LPG, and complementation of a deltageh strain with a Geh expression plasmid restored extracellular a15-LPG formation. Orlistat, a covalent inhibitor of Geh, also attenuated extracellular a15-LPG accumulation. Purified Geh hydrolyzed the 1-position acyl chain of PG and generated only a15-LPG from a S. aureus lipid mixture. The Geh product was 2-a15-LPG, which spontaneously isomerizes with time to a mixture of 1- and 2-a15-LPG. Docking PG in the Geh active site provides a structural rationale for the positional specificity of Geh. These data demonstrate a physiological role for Geh phospholipase A1 activity in S. aureus membrane phospholipid turnover. IMPORTANCE Glycerol ester hydrolase, Geh, is an abundant secreted lipase whose expression is controlled by the accessory gene regulator (Agr) quorum-sensing signal transduction pathway. Geh is thought to have a role in virulence based on its ability to hydrolyze host lipids at the infection site to provide fatty acids for membrane biogenesis and substrates for oleate hydratase, and Geh inhibits immune cell activation by hydrolyzing lipoprotein glycerol esters. The discovery that Geh is the major contributor to the formation and release of a15-LPG reveals an unappreciated physiological role for Geh acting as a phospholipase A1 in the degradation of S. aureus membrane phosphatidylglycerol. The role(s) for extracellular a15-LPG in S. aureus biology remain to be elucidated.
        
Title: 3-D structure modelling of the Staphylococcus simulans lipase: conformational changes, substrate specificity and novel structural features Frikha F, Ladjimi M, Gargouri Y, Miled N Ref: FEMS Microbiology Letters, 286:207, 2008 : PubMed
We have modelled, using the CHARMM27 energy force field, the structures of closed and open forms of Staphylococcus simulans lipase (SSL) on the basis of the crystal structures of Bacillus stearothermophilus and Staphylococcus hyicus lipases, respectively. The models suggested the presence of a main lid and a second lid that may act with the former as a double door to control the access to the active site. Superimposition of both closed and open forms of SSL allowed us to determine the hinge regions allowing the movements of the main and the second lid upon lipase activation. The flexibility of these hinge regions was checked by molecular dynamics simulations. The SSL models also allowed us to identify key residues involved in binding substrates, calcium or zinc ions.
        
Title: Importance of the residue Asp 290 on chain length selectivity and catalytic efficiency of recombinant Staphylococcus simulans lipase expressed in E. coli Sayari A, Mosbah H, Gargouri Y Ref: Mol Biotechnol, 36:14, 2007 : PubMed
In addition to their physiological importance, microbial lipases, like staphylococcal ones, are of considerable commercial interest for biotechnological applications such as detergents, food production, and pharmaceuticals and industrial synthesis of fine chemicals. The gene encoding the extracellular lipase of Staphylococcus simulans (SSL) was subcloned in the pET-14b expression vector and expressed in Esherichia coli BL21 (DE3). The wild-type SSL was expressed as amino terminal His6-tagged recombinant protein. One-step purification of the recombinant lipase was achieved with nickel metal affinity column. The purified His-tagged SSL (His6-SSL) is able to hydrolyse triacylglycerols without chain length selectivity. The major differences among lipases are reflected in their chemical specificity in the hydrolysis of peculiar ester bonds, and their respective capacity to hydrolyse substrates having different physico-chemical properties. It has been proposed, using homology alignment, that the region around the residue 290 of Staphylococcus hyicus lipase could be involved in the selection of the substrate. To evaluate the importance of this environment, the residue Asp290 of Staphylococcus simulans lipase was mutated to Ala using site-directed mutagenesis. The mutant expression plasmid was also overexpressed in Esherichia coli and purified with a nickel metal affinity column. The substitution of Asp290 by Ala was accompanied by a significant shift of the acyl-chain length specificity of the mutant towards short chain fatty acid esters. Kinetic studies of wild-type SSL and its mutant D290A were carried out, and show essentially that the catalytic efficiency (k cat /K M ) of the mutant was affected. Our results confirmed that Asp290 is important for the chain length selectivity and catalytic efficiency of Staphylococcus simulans lipase.
        
23 lessTitle: The Phospholipase A1 Activity of Glycerol Ester Hydrolase (Geh) Is Responsible for Extracellular 2-12(S)-Methyltetradecanoyl-Lysophosphatidylglycerol Production in Staphylococcus aureus Subramanian C, Frank MW, Yun MK, Rock CO Ref: mSphere, :e0003123, 2023 : PubMed
Phosphatidylglycerol (PG) is the major membrane phospholipid of Staphylococcus aureus and predominately consists of molecular species with <=16-carbon acyl chains in the 1-position and anteiso 12(S)-methyltetradecaonate (a15) esterified at the 2-position. The analysis of the growth media for PG-derived products shows S. aureus releases essentially pure 2-12(S)-methyltetradecanoyl-sn-glycero-3-phospho-1'-sn-glycerol (a15:0-LPG) derived from the hydrolysis of the 1-position of PG into the environment. The cellular lysophosphatidylglycerol (LPG) pool is dominated by a15-LPG but also consists of <=16-LPG species arising from the removal of the 2-position. Mass tracing experiments confirmed a15-LPG was derived from isoleucine metabolism. A screen of candidate secreted lipase knockout strains pinpointed glycerol ester hydrolase (geh) as the gene required for generating extracellular a15-LPG, and complementation of a deltageh strain with a Geh expression plasmid restored extracellular a15-LPG formation. Orlistat, a covalent inhibitor of Geh, also attenuated extracellular a15-LPG accumulation. Purified Geh hydrolyzed the 1-position acyl chain of PG and generated only a15-LPG from a S. aureus lipid mixture. The Geh product was 2-a15-LPG, which spontaneously isomerizes with time to a mixture of 1- and 2-a15-LPG. Docking PG in the Geh active site provides a structural rationale for the positional specificity of Geh. These data demonstrate a physiological role for Geh phospholipase A1 activity in S. aureus membrane phospholipid turnover. IMPORTANCE Glycerol ester hydrolase, Geh, is an abundant secreted lipase whose expression is controlled by the accessory gene regulator (Agr) quorum-sensing signal transduction pathway. Geh is thought to have a role in virulence based on its ability to hydrolyze host lipids at the infection site to provide fatty acids for membrane biogenesis and substrates for oleate hydratase, and Geh inhibits immune cell activation by hydrolyzing lipoprotein glycerol esters. The discovery that Geh is the major contributor to the formation and release of a15-LPG reveals an unappreciated physiological role for Geh acting as a phospholipase A1 in the degradation of S. aureus membrane phosphatidylglycerol. The role(s) for extracellular a15-LPG in S. aureus biology remain to be elucidated.
        
Title: Structure elucidation of Staphylococcus capitis lipase. Molecular dynamics simulations to investigate the effects of calcium and zinc ions on the structural stability Rmili F, Frikha F, Chamkha M, Sayari A, Fendri A Ref: J Biomol Struct Dyn, :1, 2022 : PubMed
Cold-adapted and organic solvent tolerant lipases have significant potential in a wide range of synthetic reactions in industry. But there are no sufficient studies on how these enzymes interacts with their substrates. Herein, the predicted structure and function of the Staphylococcus capitis lipase (SCL) are studied. Given the high amino acid sequence homology with the Staphylococcus simulans lipase (SSL), 3D structure models of closed and open forms of the S. capitis lipase were built using the structure of SSL as template. The models suggested the presence of a main lid and a second lid that may act with the former as a double door to control the access to the active site. The SCL models also allowed us to identify key residues involved in binding substrates, calcium or zinc ions. By following this model and utilizing molecular dynamics (MD) simulations, the stability of the S. capitis lipase at low temperatures could be explained in the presence and in the absence of calcium and zinc. Due to its thermolability, the SCL is extremely valuable for different biotechnological applications in a wide variety of industries from molecular biology to detergency to food and beverage preparation.Communicated by Ramaswamy H. Sarma.
Staphylococcus aureus lipase (SAL), a triacylglycerol esterase, is an important virulence factor and may be a therapeutic target for infectious diseases. Herein, we determined the 3D structure of native SAL, the mutated S116A inactive form, and the inhibitor complex using the anti-obesity drug orlistat to aid in drug development. The determined crystal structures showed a typical alpha/beta hydrolase motif with a dimeric form. Fatty acids bound near the active site in native SAL and inactive S116A mutant structures. We found that orlistat potently inhibits SAL activity, and it covalently bound to the catalytic Ser116 residue. This is the first report detailing orlistat-lipase binding. It provides structure-based information on the production of potent anti-SAL drugs and lipase inhibitors. These results also indicated that orlistat can be repositioned to treat bacterial diseases.
        
Title: Bacterial lipolysis of immune-activating ligands promotes evasion of innate defenses Chen X, Alonzo F, 3rd Ref: Proc Natl Acad Sci U S A, 116:3764, 2019 : PubMed
Commensal and pathogenic bacteria hydrolyze host lipid substrates with secreted lipases and phospholipases for nutrient acquisition, colonization, and infection. Bacterial lipase activity on mammalian lipids and phospholipids can promote release of free fatty acids from lipid stores, detoxify antimicrobial lipids, and facilitate membrane dissolution. The gram-positive bacterium Staphylococcus aureus secretes at least two lipases, Sal1 and glycerol ester hydrolase (Geh), with specificities for short- and long-chain fatty acids, respectively, each with roles in the hydrolysis of environmental lipids. In a recent study from our group, we made the unexpected observation that Geh released by S. aureus inhibits activation of innate immune cells. Herein, we investigated the possibility that S. aureus lipases interface with the host immune system to blunt innate immune recognition of the microbe. We found that the Geh lipase, but not other S. aureus lipases, prevents activation of innate cells in culture. Mutation of geh leads to enhancement of proinflammatory cytokine production during infection, increased innate immune activity, and improved clearance of the bacterium in infected tissue. These in vitro and in vivo effects on innate immunity were not due to direct functions of the lipase on mammalian cells, but rather a result of inactivation of S. aureus lipoproteins, a major pathogen-associated molecular pattern (PAMP) of extracellular gram-positive bacteria, via ester hydrolysis. Altogether, these studies provide insight into an adaptive trait that masks microbial recognition by innate immune cells through targeted inactivation of a broadly conserved PAMP.
        
Title: Staphylococcus aureus lipase: purification, kinetic characterization, crystallization and crystallographic study Tanaka M, Kamitani S, Kitadokoro K Ref: Acta Crystallographica F Struct Biol Commun, 74:567, 2018 : PubMed
Staphylococcus aureus lipase (SAL), a triacylglycerol esterase, is an important virulence factor in S. aureus and may be a therapeutic target for infectious diseases caused by S. aureus. For the purposes of anti-SAL drug development using structure-based drug design, X-ray crystallographic analysis of SAL overexpressed in Escherichia coli was performed. The recombinant protein was purified using a three-step protocol involving immobilized metal-affinity chromatography, cation-exchange chromatography and anion-exchange chromatography flowthrough methods, yielding 40 mg of protein per litre of bacterial culture. Crystals were obtained using the sitting-drop vapor-diffusion technique. Diffraction data to 3.0 A resolution were collected on the BL44XU beamline at SPring-8 at the zinc peak of 1.2842 A for SAD phasing. The crystals belonged to space group P4122 or P4322, with unit-cell parameters a = 131.0, b = 131.0, c = 250.6 A, and are likely to contain four SAL molecules (408 residues) per asymmetric unit.
Community methicillin-resistant Staphylococcus aureus (cMRSA) is an emerging issue that has resulted in multiple worldwide epidemics. We report the first complete genome sequence of an ST93-MRSA-IV clinical isolate that caused severe invasive infection and a familial outbreak of skin infection. This isolate is a representative of the most common Australian clone of cMRSA that is more distantly related to the previously sequenced genomes of S. aureus.
Phenotypic biotyping has traditionally been used to differentiate bacteria occupying distinct ecological niches such as host species. For example, the capacity of Staphylococcus aureus from sheep to coagulate ruminant plasma, reported over 60 years ago, led to the description of small ruminant and bovine S. aureus ecovars. The great majority of small ruminant isolates are represented by a single, widespread clonal complex (CC133) of S. aureus, but its evolutionary origin and the molecular basis for its host tropism remain unknown. Here, we provide evidence that the CC133 clone evolved as the result of a human to ruminant host jump followed by adaptive genome diversification. Comparative whole-genome sequencing revealed molecular evidence for host adaptation including gene decay and diversification of proteins involved in host-pathogen interactions. Importantly, several novel mobile genetic elements encoding virulence proteins with attenuated or enhanced activity in ruminants were widely distributed in CC133 isolates, suggesting a key role in its host-specific interactions. To investigate this further, we examined the activity of a novel staphylococcal pathogenicity island (SaPIov2) found in the great majority of CC133 isolates which encodes a variant of the chromosomally encoded von Willebrand-binding protein (vWbp(Sov2)), previously demonstrated to have coagulase activity for human plasma. Remarkably, we discovered that SaPIov2 confers the ability to coagulate ruminant plasma suggesting an important role in ruminant disease pathogenesis and revealing the origin of a defining phenotype of the classical S. aureus biotyping scheme. Taken together, these data provide broad new insights into the origin and molecular basis of S. aureus ruminant host specificity.
        
Title: Whole genome analysis of a livestock-associated methicillin-resistant Staphylococcus aureus ST398 isolate from a case of human endocarditis Schijffelen MJ, Boel CH, van Strijp JA, Fluit AC Ref: BMC Genomics, 11:376, 2010 : PubMed
BACKGROUND: Recently, a new livestock-associated methicillin-resistant Staphylococcus aureus (MRSA) Sequence Type 398 (ST398) isolate has emerged worldwide. Although there have been reports of invasive disease in humans, MRSA ST398 colonization is much more common in livestock and demonstrates especially high prevalence rates in pigs and calves. The aim of this study was to compare the genome sequence of an ST398 MRSA isolate with other S. aureus genomes in order to identify genetic traits that may explain the success of this particular lineage. Therefore, we determined the whole genome sequence of S0385, an MRSA ST398 isolate from a human case of endocarditis. RESULTS: The entire genome sequence of S0385 demonstrated considerable accessory genome content differences relative to other S. aureus genomes. Several mobile genetic elements that confer antibiotic resistance were identified, including a novel composite of an type V (5C2&5) Staphylococcal Chromosome Cassette mec (SCCmec) with distinct joining (J) regions. The presence of multiple integrative conjugative elements combined with the absence of a type I restriction and modification system on one of the two nuSa islands, could enhance horizontal gene transfer in this strain. The ST398 MRSA isolate carries a unique pathogenicity island which encodes homologues of two excreted virulence factors; staphylococcal complement inhibitor (SCIN) and von Willebrand factor-binding protein (vWbp). However, several virulence factors such as enterotoxins and phage encoded toxins, including Panton-Valentine leukocidin (PVL), were not identified in this isolate. CONCLUSIONS: Until now MRSA ST398 isolates did not cause frequent invasive disease in humans, which may be due to the absence of several common virulence factors. However, the proposed enhanced ability of these isolates to acquire mobile elements may lead to the rapid acquisition of determinants which contribute to virulence in human infections.
The impact of globalization on the emergence and spread of pathogens is an important veterinary and public health issue. Staphylococcus aureus is a notorious human pathogen associated with serious nosocomial and community-acquired infections. In addition, S. aureus is a major cause of animal diseases including skeletal infections of poultry, which are a large economic burden on the global broiler chicken industry. Here, we provide evidence that the majority of S. aureus isolates from broiler chickens are the descendants of a single human-to-poultry host jump that occurred approximately 38 years ago (range, 30 to 63 years ago) by a subtype of the worldwide human ST5 clonal lineage unique to Poland. In contrast to human subtypes of the ST5 radiation, which demonstrate strong geographic clustering, the poultry ST5 clade was distributed in different continents, consistent with wide dissemination via the global poultry industry distribution network. The poultry ST5 clade has undergone genetic diversification from its human progenitor strain by acquisition of novel mobile genetic elements from an avian-specific accessory gene pool, and by the inactivation of several proteins important for human disease pathogenesis. These genetic events have resulted in enhanced resistance to killing by chicken heterophils, reflecting avian host-adaptive evolution. Taken together, we have determined the evolutionary history of a major new animal pathogen that has undergone rapid avian host adaptation and intercontinental dissemination. These data provide a new paradigm for the impact of human activities on the emergence of animal pathogens.
        
Title: Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K Ref: Journal of Bacteriology, 190:300, 2008 : PubMed
Strains of Staphylococcus aureus, an important human pathogen, display up to 20% variability in their genome sequence, and most sequence information is available for human clinical isolates that have not been subjected to genetic analysis of virulence attributes. S. aureus strain Newman, which was also isolated from a human infection, displays robust virulence properties in animal models of disease and has already been extensively analyzed for its molecular traits of staphylococcal pathogenesis. We report here the complete genome sequence of S. aureus Newman, which carries four integrated prophages, as well as two large pathogenicity islands. In agreement with the view that S. aureus Newman prophages contribute important properties to pathogenesis, fewer virulence factors are found outside of the prophages than for the highly virulent strain MW2. The absence of drug resistance genes reflects the general antibiotic-susceptible phenotype of S. aureus Newman. Phylogenetic analyses reveal clonal relationships between the staphylococcal strains Newman, COL, NCTC8325, and USA300 and a greater evolutionary distance to strains MRSA252, MW2, MSSA476, N315, Mu50, JH1, JH9, and RF122. However, polymorphism analysis of two large pathogenicity islands distributed among these strains shows that the two islands were acquired independently from the evolutionary pathway of the chromosomal backbones of staphylococcal genomes. Prophages and pathogenicity islands play central roles in S. aureus virulence and evolution.
        
Title: 3-D structure modelling of the Staphylococcus simulans lipase: conformational changes, substrate specificity and novel structural features Frikha F, Ladjimi M, Gargouri Y, Miled N Ref: FEMS Microbiology Letters, 286:207, 2008 : PubMed
We have modelled, using the CHARMM27 energy force field, the structures of closed and open forms of Staphylococcus simulans lipase (SSL) on the basis of the crystal structures of Bacillus stearothermophilus and Staphylococcus hyicus lipases, respectively. The models suggested the presence of a main lid and a second lid that may act with the former as a double door to control the access to the active site. Superimposition of both closed and open forms of SSL allowed us to determine the hinge regions allowing the movements of the main and the second lid upon lipase activation. The flexibility of these hinge regions was checked by molecular dynamics simulations. The SSL models also allowed us to identify key residues involved in binding substrates, calcium or zinc ions.
        
Title: Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K Ref: Antimicrobial Agents & Chemotherapy, 52:45, 2008 : PubMed
Multistep genetic alteration is required for methicillin-resistant Staphylococcus aureus (MRSA) to achieve the level of vancomycin resistance of vancomycin-intermediate S. aureus (VISA). In the progression of vancomycin resistance, strains with heterogeneous vancomycin resistance, designated hetero-VISA, are observed. In studying the whole-genome sequencing of the representative hetero-VISA strain Mu3 and comparing it with that of closely related MRSA strains Mu50 (VISA) and N315 (vancomycin-susceptible S. aureus [VSSA]), we identified a mutation in the response regulator of the graSR two-component regulatory system. Introduction of mutated graR, designated graR*, but not intact graR, designated graRn, could convert the hetero-VISA phenotype of Mu3 into a VISA phenotype which was comparable to that of Mu50. The same procedure did not appreciably increase the vancomycin resistance of VSSA strain N315, indicating that graR* expression was effective only in the physiological milieu of hetero-VISA cell to achieve a VISA phenotype. Interestingly, the overexpression of graR* increased the daptomycin MICs in both Mu3 and N315 and decreased the oxacillin MIC in N315.
BACKGROUND: Nasal carriage of Staphylococcus aureus is a major risk factor in clinical and community settings due to the range of etiologies caused by the organism. We have identified unique immunological and ultrastructural properties associated with nasal carriage isolates denoting a role for bacterial factors in nasal carriage. However, despite extensive molecular level characterizations by several groups suggesting factors necessary for colonization on nasal epithelium, genetic determinants of nasal carriage are unknown. Herein, we have set a genomic foundation for unraveling the bacterial determinants of nasal carriage in S. aureus. RESULTS: MLST analysis revealed no lineage specific differences between carrier and non-carrier strains suggesting a role for mobile genetic elements. We completely sequenced a model carrier isolate (D30) and a model non-carrier strain (930918-3) to identify differential gene content. Comparison revealed the presence of 84 genes unique to the carrier strain and strongly suggests a role for Type VII secretion systems in nasal carriage. These genes, along with a putative pathogenicity island (SaPIBov) present uniquely in the carrier strains are likely important in affecting carriage. Further, PCR-based genotyping of other clinical isolates for a specific subset of these 84 genes raise the possibility of nasal carriage being caused by multiple gene sets. CONCLUSION: Our data suggest that carriage is likely a heterogeneic phenotypic trait and implies a role for nucleotide level polymorphism in carriage. Complete genome level analyses of multiple carriage strains of S. aureus will be important in clarifying molecular determinants of S. aureus nasal carriage.
BACKGROUND: The majority of Staphylococcus aureus isolates that are recovered from either serious infections in humans or from mastitis in cattle represent genetically distinct sets of clonal groups. Moreover, population genetic analyses have provided strong evidence of host specialization among S. aureus clonal groups associated with human and ruminant infection. However, the molecular basis of host specialization in S. aureus is not understood. METHODOLOGY/PRINCIPAL FINDINGS: We sequenced the genome of strain ET3-1, a representative isolate of a common bovine mastitis-causing S. aureus clone. Strain ET3-1 encodes several genomic elements that have not been previously identified in S. aureus, including homologs of virulence factors from other gram-positive pathogens. Relative to the other sequenced S. aureus associated with human infection, allelic variation in ET3-1 was high among virulence and surface-associated genes involved in host colonization, toxin production, iron metabolism, antibiotic resistance, and gene regulation. Interestingly, a number of well-characterized S. aureus virulence factors, including protein A and clumping factor A, exist as pseudogenes in ET3-1. Whole-genome DNA microarray hybridization revealed considerable similarity in the gene content of highly successful S. aureus clones associated with bovine mastitis, but not among those clones that are only infrequently recovered from bovine hosts. CONCLUSIONS/SIGNIFICANCE: Whole genome sequencing and comparative genomic analyses revealed a set of molecular genetic features that distinguish clones of highly successful bovine-associated S. aureus optimized for mastitis pathogenesis in cattle from those that infect human hosts or are only infrequently recovered from bovine sources. Further, the results suggest that modern bovine specialist clones diverged from a common ancestor resembling human-associated S. aureus clones through a combination of foreign DNA acquisition and gene decay.
BACKGROUND: Community acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) increasingly causes disease worldwide. USA300 has emerged as the predominant clone causing superficial and invasive infections in children and adults in the USA. Epidemiological studies suggest that USA300 is more virulent than other CA-MRSA. The genetic determinants that render virulence and dominance to USA300 remain unclear. RESULTS: We sequenced the genomes of two pediatric USA300 isolates: one CA-MRSA and one CA-methicillin susceptible (MSSA), isolated at Texas Children's Hospital in Houston. DNA sequencing was performed by Sanger dideoxy whole genome shotgun (WGS) and 454 Life Sciences pyrosequencing strategies. The sequence of the USA300 MRSA strain was rigorously annotated. In USA300-MRSA 2658 chromosomal open reading frames were predicted and 3.1 and 27 kilobase (kb) plasmids were identified. USA300-MSSA contained a 20 kb plasmid with some homology to the 27 kb plasmid found in USA300-MRSA. Two regions found in US300-MRSA were absent in USA300-MSSA. One of these carried the arginine deiminase operon that appears to have been acquired from S. epidermidis. The USA300 sequence was aligned with other sequenced S. aureus genomes and regions unique to USA300 MRSA were identified. CONCLUSION: USA300-MRSA is highly similar to other MRSA strains based on whole genome alignments and gene content, indicating that the differences in pathogenesis are due to subtle changes rather than to large-scale acquisition of virulence factor genes. The USA300 Houston isolate differs from another sequenced USA300 strain isolate, derived from a patient in San Francisco, in plasmid content and a number of sequence polymorphisms. Such differences will provide new insights into the evolution of pathogens.
        
Title: Importance of the residue Asp 290 on chain length selectivity and catalytic efficiency of recombinant Staphylococcus simulans lipase expressed in E. coli Sayari A, Mosbah H, Gargouri Y Ref: Mol Biotechnol, 36:14, 2007 : PubMed
In addition to their physiological importance, microbial lipases, like staphylococcal ones, are of considerable commercial interest for biotechnological applications such as detergents, food production, and pharmaceuticals and industrial synthesis of fine chemicals. The gene encoding the extracellular lipase of Staphylococcus simulans (SSL) was subcloned in the pET-14b expression vector and expressed in Esherichia coli BL21 (DE3). The wild-type SSL was expressed as amino terminal His6-tagged recombinant protein. One-step purification of the recombinant lipase was achieved with nickel metal affinity column. The purified His-tagged SSL (His6-SSL) is able to hydrolyse triacylglycerols without chain length selectivity. The major differences among lipases are reflected in their chemical specificity in the hydrolysis of peculiar ester bonds, and their respective capacity to hydrolyse substrates having different physico-chemical properties. It has been proposed, using homology alignment, that the region around the residue 290 of Staphylococcus hyicus lipase could be involved in the selection of the substrate. To evaluate the importance of this environment, the residue Asp290 of Staphylococcus simulans lipase was mutated to Ala using site-directed mutagenesis. The mutant expression plasmid was also overexpressed in Esherichia coli and purified with a nickel metal affinity column. The substitution of Asp290 by Ala was accompanied by a significant shift of the acyl-chain length specificity of the mutant towards short chain fatty acid esters. Kinetic studies of wild-type SSL and its mutant D290A were carried out, and show essentially that the catalytic efficiency (k cat /K M ) of the mutant was affected. Our results confirmed that Asp290 is important for the chain length selectivity and catalytic efficiency of Staphylococcus simulans lipase.
BACKGROUND: USA300, a clone of meticillin-resistant Staphylococcus aureus, is a major source of community-acquired infections in the USA, Canada, and Europe. Our aim was to sequence its genome and compare it with those of other strains of S aureus to try to identify genes responsible for its distinctive epidemiological and virulence properties. METHODS: We ascertained the genome sequence of FPR3757, a multidrug resistant USA300 strain, by random shotgun sequencing, then compared it with the sequences of ten other staphylococcal strains. FINDINGS: Compared with closely related S aureus, we noted that almost all of the unique genes in USA300 clustered in novel allotypes of mobile genetic elements. Some of the unique genes are involved in pathogenesis, including Panton-Valentine leucocidin and molecular variants of enterotoxin Q and K. The most striking feature of the USA300 genome is the horizontal acquisition of a novel mobile genetic element that encodes an arginine deiminase pathway and an oligopeptide permease system that could contribute to growth and survival of USA300. We did not detect this element, termed arginine catabolic mobile element (ACME), in other S aureus strains. We noted a high prevalence of ACME in S epidermidis, suggesting not only that ACME transfers into USA300 from S epidermidis, but also that this element confers a selective advantage to this ubiquitous commensal of the human skin. INTERPRETATION: USA300 has acquired mobile genetic elements that encode resistance and virulence determinants that could enhance fitness and pathogenicity.
Staphylococcus aureus is an opportunistic pathogen and the major causative agent of numerous hospital- and community-acquired infections. Staphylococcus epidermidis has emerged as a causative agent of infections often associated with implanted medical devices. We have sequenced the approximately 2.8-Mb genome of S. aureus COL, an early methicillin-resistant isolate, and the approximately 2.6-Mb genome of S. epidermidis RP62a, a methicillin-resistant biofilm isolate. Comparative analysis of these and other staphylococcal genomes was used to explore the evolution of virulence and resistance between these two species. The S. aureus and S. epidermidis genomes are syntenic throughout their lengths and share a core set of 1,681 open reading frames. Genome islands in nonsyntenic regions are the primary source of variations in pathogenicity and resistance. Gene transfer between staphylococci and low-GC-content gram-positive bacteria appears to have shaped their virulence and resistance profiles. Integrated plasmids in S. epidermidis carry genes encoding resistance to cadmium and species-specific LPXTG surface proteins. A novel genome island encodes multiple phenol-soluble modulins, a potential S. epidermidis virulence factor. S. epidermidis contains the cap operon, encoding the polyglutamate capsule, a major virulence factor in Bacillus anthracis. Additional phenotypic differences are likely the result of single nucleotide polymorphisms, which are most numerous in cell envelope proteins. Overall differences in pathogenicity can be attributed to genome islands in S. aureus which encode enterotoxins, exotoxins, leukocidins, and leukotoxins not found in S. epidermidis.
Staphylococcus aureus is an important nosocomial and community-acquired pathogen. Its genetic plasticity has facilitated the evolution of many virulent and drug-resistant strains, presenting a major and constantly changing clinical challenge. We sequenced the approximately 2.8-Mbp genomes of two disease-causing S. aureus strains isolated from distinct clinical settings: a recent hospital-acquired representative of the epidemic methicillin-resistant S. aureus EMRSA-16 clone (MRSA252), a clinically important and globally prevalent lineage; and a representative of an invasive community-acquired methicillin-susceptible S. aureus clone (MSSA476). A comparative-genomics approach was used to explore the mechanisms of evolution of clinically important S. aureus genomes and to identify regions affecting virulence and drug resistance. The genome sequences of MRSA252 and MSSA476 have a well conserved core region but differ markedly in their accessory genetic elements. MRSA252 is the most genetically diverse S. aureus strain sequenced to date: approximately 6% of the genome is novel compared with other published genomes, and it contains several unique genetic elements. MSSA476 is methicillin-susceptible, but it contains a novel Staphylococcal chromosomal cassette (SCC) mec-like element (designated SCC(476)), which is integrated at the same site on the chromosome as SCCmec elements in MRSA strains but encodes a putative fusidic acid resistance protein. The crucial role that accessory elements play in the rapid evolution of S. aureus is clearly illustrated by comparing the MSSA476 genome with that of an extremely closely related MRSA community-acquired strain; the differential distribution of large mobile elements carrying virulence and drug-resistance determinants may be responsible for the clinically important phenotypic differences in these strains.
BACKGROUND: A new type of meticillin-resistant Staphylococcus aureus (MRSA), designated community-acquired MRSA, is becoming increasingly noticeable in the community, some strains of which cause fatal infections in otherwise healthy individuals. By contrast with hospital-acquired MRSA, community-acquired MRSA is more susceptible to non b-lactam antibiotics. We investigated the high virulence potential of certain strains of this bacterium. METHODS: We ascertained the whole genome sequence of MW2, a strain of community-acquired MRSA, by shotgun cloning and sequencing. MW2 caused fatal septicaemia and septic arthritis in a 16-month-old girl in North Dakota, USA, in 1998. The genome of this strain was compared with those of hospital-acquired MRSA strains, including N315 and Mu50. FINDINGS: Meticillin resistance gene (mecA) in MW2 was carried by a novel allelic form (type IVa) of staphylococcal cassette chromosome mec (SCCmec), by contrast with type II in N315 and Mu50. Type IVa SCCmec did not carry any of the multiple antibiotic resistance genes reported in type II SCCmec. By contrast, 19 additional virulence genes were recorded in the MW2 genome. All but two of these virulence genes were noted in four of the seven genomic islands of MW2. INTERPRETATION: MW2 carried a range of virulence and resistance genes that was distinct from those displayed on the chromosomes of extant S aureus strains. Most genes were carried by specific allelic forms of genomic islands in the MW2 chromosome. The combination of allelic forms of genomic islands is the genetic basis that determines the pathogenicity of medically important phenotypes of S aureus, including those of community-acquired MRSA strains.
BACKGROUND: Staphylococcus aureus is one of the major causes of community-acquired and hospital-acquired infections. It produces numerous toxins including superantigens that cause unique disease entities such as toxic-shock syndrome and staphylococcal scarlet fever, and has acquired resistance to practically all antibiotics. Whole genome analysis is a necessary step towards future development of countermeasures against this organism. METHODS: Whole genome sequences of two related S aureus strains (N315 and Mu50) were determined by shot-gun random sequencing. N315 is a meticillin-resistant S aureus (MRSA) strain isolated in 1982, and Mu50 is an MRSA strain with vancomycin resistance isolated in 1997. The open reading frames were identified by use of GAMBLER and GLIMMER programs, and annotation of each was done with a BLAST homology search, motif analysis, and protein localisation prediction. FINDINGS: The Staphylococcus genome was composed of a complex mixture of genes, many of which seem to have been acquired by lateral gene transfer. Most of the antibiotic resistance genes were carried either by plasmids or by mobile genetic elements including a unique resistance island. Three classes of new pathogenicity islands were identified in the genome: a toxic-shock-syndrome toxin island family, exotoxin islands, and enterotoxin islands. In the latter two pathogenicity islands, clusters of exotoxin and enterotoxin genes were found closely linked with other gene clusters encoding putative pathogenic factors. The analysis also identified 70 candidates for new virulence factors. INTERPRETATION: The remarkable ability of S aureus to acquire useful genes from various organisms was revealed through the observation of genome complexity and evidence of lateral gene transfer. Repeated duplication of genes encoding superantigens explains why S aureus is capable of infecting humans of diverse genetic backgrounds, eliciting severe immune reactions. Investigation of many newly identified gene products, including the 70 putative virulence factors, will greatly improve our understanding of the biology of staphylococci and the processes of infectious diseases caused by S aureus.
        
Title: Biochemical and molecular characterization of Staphylococcus simulans lipase Sayari A, Agrebi N, Jaoua S, Gargouri Y Ref: Biochimie, 83:863, 2001 : PubMed
Staphylococcus simulans strain secretes a non-induced lipase in the culture medium. Staphylococcus simulans lipase (SSL), purified to homogeneity, is a tetrameric protein (160 kDa) corresponding to the association of four lipase molecules. The 30 N-terminal amino acid residues were sequenced. This sequence is identical to the one of Staphylococcus aureus PS54 lipase (SAL PS54) and exhibits a high degree of homology with Staphylococcus aureus NCTC8530 lipase (SAL NCTC8530), Staphylococcus hyicus lipase (SHL) and Staphylococcus epidermis RP62A lipase (SEL RP62A) sequences. But the cloning and sequencing of the part of the gene encoding the mature lipase show some differences from SAL PS54 sequence, which suggest that it is a new sequence. The lipase activity was maximal at pH 8.5 and 37 degrees C. SSL is able to hydrolyze triacylglycerols without chain length specificity. A specific activity of about 1000 U/mg was measured on tributyrin or triolein as substrate at 37 degrees C and at pH 8.5 in the presence of 3 mM CaCl(2). In contrast to other staphylococcal lipases previously characterized, Ca(2+) is not required to express the activity of SSL. SSL was found to be stable between pH 4 and pH 9. The enzyme is inactivated after a few minutes when incubated at 60 degrees C. Using tripropionin as substrate, SSL does not present the interfacial activation phenomenon. In contrast to many lipases, SSL is able to hydrolyze its substrate in the presence of bile salts or amphiphilic proteins.
        
Title: Staphylococcal lipases: biochemical and molecular characterization Rosenstein R, Gotz F Ref: Biochimie, 82:1005, 2000 : PubMed
To date, the nucleotide sequences of nine different lipase genes from six Staphylococcus species, three from S. epidermidis, two from S. aureus, and one each from S. haemolyticus, S. hyicus, S. warneri, and S. xylosus, have been determined. All deduced lipase proteins are similarly organized as pre-pro-proteins, with pre-regions corresponding to a signal peptide of 35 to 38 amino acids, a pro-peptide of 207 to 321 amino acids with an overall hydrophilic character, and a mature peptide comprising 383 to 396 amino acids. The lipases are secreted in the pro-form and are afterwards processed to the mature form by specific proteases. The pro-peptide of the S. hyicus lipase is necessary for efficient translocation and for protection against proteolytic degradation. Despite being very similar in their primary structures the staphylococcal lipases show significant differences in their biochemical and catalytic properties, such as substrate selectivity, pH optimum and interfacial activation. The lipase from S. hyicus is unique among the staphylococcal and bacterial lipases in that it has not only lipase activity, but also a high phospho-lipase activity. All staphylococcal lipases are dependent on Ca(2+), which is thought to have a function in stabilizing the tertiary structure of the lipases. Evidence exists that staphylococcal lipases like other bacterial lipases, possess a lid-like domain that might be involved in the interfacial activation of these enzymes.
        
Title: Staphylococcal lipases: molecular characterisation, secretion, and processing Gotz F, Verheij HM, Rosenstein R Ref: Chemistry & Physic of Lipids, 93:15, 1998 : PubMed
Up to date five different staphylococcal lipase genes, two of Staphylococcus aureus (sal-1 and sal-2), two of Staphylococcus epidermidis (sel-1 and sel-2) and one of Staphylococcus hyicus (sh1) have been cloned and sequenced. All corresponding proteins are organised as pre-pro-enzymes: the pre-region represents the signal peptide, the pro-region has a length between 207 and 267 amino acids, and the mature part comprises 380 to 400 amino acids. We found that the lipases are secreted in the pro-lipase form. The processing of the pro-form to the mature enzyme occurs extracellular by a specific protease. Interestingly the pro-lipase reveals not much less activity compared to the mature lipase. There are evidences that the pro-region acts as an intramolecular chaperone which facilitates translocation not only of the native lipase but also of a number of completely unrelated proteins fused to the pro-peptide. It was also observed that the pro-region protects the proteins from proteolytic degradation. While the Staphylococcus aureus and Staphylococcus epidermidis lipases have only lipase (esterase) activity, the related Staphylococcus hyicus enzyme (SHL) is distinguished by both lipase and phospho-lipase activity. The biochemical and catalytic properties of these lipases are described in the accompanying article (Simons, J.W., Gtz, F., Egmont, M.R. and Verheij, H.M., 1998. Staphylococcal lipases: Biochemical properties. Accompanying article).
        
Title: In vivo processing of Staphylococcus aureus lipase Rollof J, Normark S Ref: Journal of Bacteriology, 174:1844, 1992 : PubMed
The Staphylococcus aureus lipase gene encodes a 76-kDa protein. Extracellular lipase purified from culture supernatants is only 45 to 46 kDa, however. We show that the lipase is secreted in vivo as an 82-kDa protein with full enzymatic activity. It is then sequentially processed, both in culture and in cell-free supernatants, to a mature, 45- to 46-kDa protein. Protein sequencing demonstrates that the N-terminal region of the 82-kDa prolipase, comprising 295 amino acids, is cleaved from the central and C-terminal moieties, which contain the active site. A metallocysteine protease is probably responsible for initiating this processing. The extremely hydrophobic, mature lipase is resistant to further protease degradation and retains the full catalytic activity of the prolipase.
        
Title: Lysogenic conversion of staphylococcal lipase is caused by insertion of the bacteriophage L54a genome into the lipase structural gene Lee CY, Iandolo JJ Ref: Journal of Bacteriology, 166:385, 1986 : PubMed
Staphylococcus aureus PS54 manifests no lipase (geh) activity. This is due to the insertion of bacteriophage L54a DNA into the geh structural gene. The nucleotide sequence of this 2,968-base-pair DNA fragment was determined. Lipase deduced from the nucleotide sequence is a polypeptide of 690 amino acids which extends from nucleotide 706 to 2776.